25 January 2016

We are delighted to announce that Professor Kathy Pritchard-Jones, Chief Medical Officer (CMO) of London Cancer, will be joining UCLH as CMO of the UCLH cancer vanguard. Professor Pritchard-Jones will be responsible for the clinical leadership and will be an integral part of the future vanguard governance board and will retain her role as CMO London Cancer, the integrated cancer system for north central and north east London and west Essex, which strives to improve health outcomes and experience of people with cancer. She will lead London Cancer’s further development as a key component of the cancer vanguard. UCLPartners will continue to support London Cancer and its ongoing programmes of work funded by Macmillan, Cancer Research UK and Camden CCG.

Dr Geoff Bellingan, Medical Director at UCLH said, “The cancer vanguard is an exciting opportunity to take the work of London Cancer to the next level. Currently, survival is poor in London, cancer patients are diagnosed too late and receive inconsistent quality of care. The Vanguard will help us tackle these problems and bring about lasting improvements for our population.”

27,000 Londoners are diagnosed with cancer every year and this is predicted to rise by 2% annually to more than 32,000 by 2022. The Cancer Vanguard will increase earlier diagnosis, reduce delays and improve patient experience and outcomes for a population of ~3.5million.